Cognitive interventions for memory and psychological well-being in aging and dementias

Dinius, Cassandra; Pocknell, Carmen E.; Caffrey, Michelle P.; Roche, Richard

doi:10.3389/fpsyg.2023.1070012

Cited by 5 publications

(1 citation statement)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The preservation of learning and memory capabilities is one of the most challenging and needed healthcare goals to achieve, considering the growth of the aged population ( Dinius et al, 2023 ). Various clinical trials have found numerous changes in the brain that may explain the negative impact of unhealthy aging on cognitive abilities.…”

Section: Memory Loss During Agingmentioning

confidence: 99%

Nicotinic acetylcholine receptors and learning and memory deficits in Neuroinflammatory diseases

2023

View full text Add to dashboard Cite

Animal survival depends on cognitive abilities such as learning and memory to adapt to environmental changes. Memory functions require an enhanced activity and connectivity of a particular arrangement of engram neurons, supported by the concerted action of neurons, glia, and vascular cells. The deterioration of the cholinergic system is a common occurrence in neurological conditions exacerbated by aging such as traumatic brain injury (TBI), posttraumatic stress disorder (PTSD), Alzheimer’s disease (AD), and Parkinson’s disease (PD). Cotinine is a cholinergic modulator with neuroprotective, antidepressant, anti-inflammatory, antioxidant, and memory-enhancing effects. Current evidence suggests Cotinine’s beneficial effects on cognition results from the positive modulation of the α7-nicotinic acetylcholine receptors (nAChRs) and the inhibition of the toll-like receptors (TLRs). The α7nAChR affects brain functions by modulating the function of neurons, glia, endothelial, immune, and dendritic cells and regulates inhibitory and excitatory neurotransmission throughout the GABA interneurons. In addition, Cotinine acting on the α7 nAChRs and TLR reduces neuroinflammation by inhibiting the release of pro-inflammatory cytokines by the immune cells. Also, α7nAChRs stimulate signaling pathways supporting structural, biochemical, electrochemical, and cellular changes in the Central nervous system during the cognitive processes, including Neurogenesis. Here, the mechanisms of memory formation as well as potential mechanisms of action of Cotinine on memory preservation in aging and neurological diseases are discussed.

show abstract

Section: Memory Loss During Agingmentioning

confidence: 99%

Nicotinic acetylcholine receptors and learning and memory deficits in Neuroinflammatory diseases

2023

View full text Add to dashboard Cite

show abstract

Development and Usability Testing of Virtual Reality (VR)-Based Reminiscence Therapy for People with Dementia

Lau,

Tang,

Gao

et al. 2024

Inf Syst Front

View full text Add to dashboard Cite

The prevalence of dementia is increasing due to a longer life expectancy and an ageing population. Cognitive impairment affects patients’ daily lives and places a financial and healthcare burden on them and their families. Reminiscence therapy (RT) is a non-pharmacological approach that has been found to enhance the quality of life for older adults with or without dementia. There is an urgent need for more functional and effective treatments, such as virtual reality (VR), which are becoming increasingly popular. VR in RT is a relatively new field, and this paper proposes a conceptual model for developing proof-of-concept virtual reality-based reminiscence therapy (VR-RT) for people with dementia, based on the 4Is: immersion, interaction, imagination, and impression. This model is intended to offer an alternative therapeutic experience for older adults with dementia. This paper demonstrates VR-RT in accordance with the results from the proposed 4Is model, to depict different periods of the olden days of scenes, such as restoring the historical objects and appearance of the citizens. The proposed VR-RT is then evaluated with the occupational therapists (OTs) through pilot testing. The findings reveal that VR-RT based on the proposed model may elicit a positive attitude and motivation in older adults with dementia. The proposed 4Is model serves to offer essential features for VR development, followed by a survey to identify suitable reminiscence materials and themes tailored to older adults with dementia. A pilot test with OTs revealed that VR-RT has the potential to improve the conditions of people with dementia. The research contributes valuable insights and lays the groundwork for future development of VR-RT for people with dementia.

show abstract

Incidence and contributing factors of dementia among people living with HIV in British Columbia, Canada, from 2002 to 2016: a retrospective cohort study

Shayegi-Nik,

Honer,

Vila-Rodriguez

et al. 2024

bmjph

View full text Add to dashboard Cite

IntroductionDementia is a progressive and debilitating disease, and people living with HIV (PLWH) often develop dementia much earlier than those not living with HIV. We estimated the incidence and prevalence of dementia and identified its key risk factors in a cohort of PLWH in British Columbia, Canada.MethodsThis retrospective cohort study used data from the Seek and Treat for Optimal Prevention of HIV/AIDS study. Eligible individuals were diagnosed with HIV, ≥40 years of age, naïve to antiretroviral therapy (ART), had no dementia at the index date and were followed for ≥1 year during 2002–2016. Our main outcome was incident dementia. We examined the effect of sociodemographic and clinical covariates on the incidence of dementia using a cause-specific hazard (CSH) model, with all-cause mortality as a competing risk event.ResultsAmong 5121 eligible PLWH, 108 (2%) developed dementia. The crude 15-year prevalence of dementia was 2.1%, and the age–sex standardised incidence rate of dementia was 4.3 (95% CI: 4.2 to 4.4) per 1000 person-years. Among the adjusted covariates, CD4 cell count<50 cells/mm3(adjusted CSH (aCSH) 8.61, 95% CI: 4.75 to 15.60), uncontrolled viremia (aCSH 1.95, 95% CI: 1.20 to 3.17), 10-year increase in age (aCSH 2.41, 95% CI: 1.89 to 3.07), schizophrenia (aCSH 2.85, 95% CI: 1.69 to 4.80), traumatic brain injury (aCSH 2.43, 95% CI: 1.59 to 3.71), delirium (aCSH 2.27, 95% CI: 1.45 to 3.55), substance use disorder (SUD) (aCSH 1.94, 95% CI: 1.18 to 3.21) and mood/anxiety disorders (aCSH 1.80, 95% CI: 1.13 to 2.86) were associated with an increased hazard for dementia. Initiating ART in 2005–2010 (versus<2000) produced an aCSH of 0.51 (95% CI: 0.30 to 0.89).ConclusionsWe demonstrated the negative role of immunosuppression and inflammation on the incidence of dementia among PLWH. Our study also calls for the enhanced integration of care services provided for HIV, mental health, SUD and other risk-inducing comorbidities as a means of lowering the risk of dementia within this population.

show abstract

Cognitive interventions for memory and psychological well-being in aging and dementias

Cited by 5 publications

References 89 publications

Nicotinic acetylcholine receptors and learning and memory deficits in Neuroinflammatory diseases

Nicotinic acetylcholine receptors and learning and memory deficits in Neuroinflammatory diseases

Development and Usability Testing of Virtual Reality (VR)-Based Reminiscence Therapy for People with Dementia

Incidence and contributing factors of dementia among people living with HIV in British Columbia, Canada, from 2002 to 2016: a retrospective cohort study

Contact Info

Product

Resources

About